The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304). 
 
“America’s hospitals and health systems are supportive of your legislation enabling the Department of Health and Human Services to require the disclosure of drug pricing information in direct-to-consumer advertising,” AHA wrote to the bill’s sponsors Sens. Charles Grassley, R-Iowa, and Richard Durbin, D-Ill. “DTC advertising has the potential to lead to high-cost prescription drugs’ overutilization, even when lower cost, equally effective options may be available. This practice of DTC advertising, is contributing to the unsustainable rate of growth in prescription drug spending, which annually consumes an increasingly large portion of health care dollars. Not only is requiring disclosure of drug pricing information in DTC advertising an important step in lowering the overall cost of prescription drugs, but it also will provide consumers with useful information as they engage in discussions with their providers about the best treatment options for their individual health care needs.”
 

Related News Articles

Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug…
Headline
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases…
Blog
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences…
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.  …
Headline
A federal judge yesterday struck down a Centers for Medicare & Medicaid Services final rule requiring drug companies to include list prices in direct-to-…